Loading stock data…
Nektar Therapeutics (NKTR)
$65.39+1.74 (+2.73%)
Market ClosedLast close Jun 29
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nektar Therapeutics in the Healthcare sector is trading at $65.39 with a market capitalization of $2.0B. Wall Street consensus targets $153.25 (8 analysts), implying a +134.4% move over the next 12 months. The stock is currently 40% below its 52-week high of $109.00, remaining 6.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +134.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $10.86M↓ | $21.81M↑ | $11.79M↑ | $11.18M↑ | $10.46M |
| Gross Profit | — | $21.81M↑ | $11.79M↑ | $11.18M↑ | $10.46M |
| Operating Income | -$38.26M↓ | -$19.09M↑ | -$31.53M↑ | -$35.78M↑ | -$44.37M |
| Net Income | -$44.90M↓ | -$36.08M↓ | -$35.52M↑ | -$41.59M↑ | -$50.88M |
Peer Comparison
JNJUNHPFE
Fundamentals
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune s...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.03B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.44%
Volume
Today's trading volume
1.06M
Recent News
What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year
This clinical-stage biopharma focused on oncology and immunology reported a notable insider sale as pipeline programs advance.
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next? The Apogee setup is the template buyers are chasing: late-stage clinical data, a meaningful addressable market, ... 3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Volatility
Recent trading moves and performance snapshot Nektar Therapeutics (NKTR) has been active in recent trading, with the stock closing at US$57.32 and showing mixed returns across different periods, including a gain year to date and declines over the past month and past 3 months. For context, the stock is up 0.3% over the past day, while it fell about 11.7% over the past week and 30% over the past month. Over the past 3 months, the share price declined roughly 17.1%. See our latest analysis for...
What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock
Nektar Therapeutics (NASDAQ:NKTR) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 11, Wedbush analyst Martin Fan decreased the price target on Nektar Therapeutics (NASDAQ:NKTR) from $95 to $80 while reiterating a Neutral rating. This revision is followed by the recent corporate earnings report, where Nektar has reaffirmed […]
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations.